EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort

Georgios Chatzis, Styliani Syntila, Harald Schuett, Harald Lapp, Carlo-Federico Fichera, Bernhard Schieffer, Bjoern Goebel, Birgit Markus, Julian Kreutz, Kiarash Sassani, Christian Waechter, Felix Ausbuettel und 1 weitere

Clinical Research in Cardiology · 19.11.2026

DOI: 10.1007/s00392-026-03055-6 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Research in Cardiology, online erschienen am 19.11.2026. Verfasst von Georgios Chatzis und 12 weiteren Autor:innen. Die Arbeit nennt 28 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Philipps-Universität Marburg.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Refractory cardiogenic shock (CS) remains associated with unacceptably high mortality despite advances in intensive-care and coronary intervention strategies. Percutaneous left ventricular support using Impella is widely used, yet real-world outcomes may differ substantially by underlying shock etiology and phenotype.

Methods

We performed a retrospective single-center cohort study of adults treated with Impella 2.5/CP for refractory CS over a 9-year period. Patients were classified as acute coronary syndrome (ACS), dilated cardiomyopathy (DCM)/myocarditis, severe aortic stenosis (AS), sepsis-associated CS, or other causes. Endpoints were all-cause in-hospital and 12-month mortality. Multivariable logistic regression adjusted for age, sex, lactate, vasoactive score, Impella type was conducted; a sensitivity model additionally included creatinine.

Results

Among 409 patients (mean age 69.99 ± 11.56 years; 75.6% male), ACS was the leading phenotype ( n = 269), followed by DCM/myocarditis ( n = 53), AS ( n = 32), sepsis-associated CS ( n = 36), and other causes ( n = 19). Impella CP was used in 227 patients (55.5%). Overall in-hospital mortality was 48.9% and differed across phenotypes, being highest in sepsis-associated CS (80.6%; chi-squared p < 0.001). Sepsis remained independently associated with in-hospital death after adjustment (adjusted odds ratio 4.65, 95% CI 2.03–12.07, p = 0.0006) for major confounders; finding was consistent after additional adjustment for creatinine (adjusted odds ratio 4.17, 95% CI 1.63–12.26, p = 0.0023). Major bleeding occurred in 14.9%, limb ischemia in 11.7%, pseudoaneurysm in 4.9%, and stroke in 1.0% of the patients. Twelve-month survival analysis also demonstrated phenotype-dependent patterns (log-rank p < 0.01).

Conclusion

In refractory CS treated with Impella outcomes are strongly phenotype-dependent. Sepsis-associated CS represents an extreme-risk phenotype with poor short- and long-term survival, suggesting phenotype-guided patient selection and prospective validation of escalation strategies.

Förderung

  • Philipps-Universität Marburg

Zitieren

APA

Chatzis, G., Syntila, S., Schuett, H., Lapp, H., Fichera, C., Schieffer, B., Goebel, B., Markus, B., Kreutz, J., Sassani, K., Waechter, C., Ausbuettel, F., & Kano, F. (2026). Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort. Clinical Research in Cardiology. https://doi.org/10.1007/s00392-026-03055-6

Vancouver

Chatzis G, Syntila S, Schuett H, Lapp H, Fichera C, Schieffer B, et al. Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort. Clinical Research in Cardiology. 2026. doi:10.1007/s00392-026-03055-6

BibTeX
@article{Chatzis2026,
  author = {Chatzis, Georgios and Syntila, Styliani and Schuett, Harald and Lapp, Harald and Fichera, Carlo-Federico and Schieffer, Bernhard and Goebel, Bjoern and Markus, Birgit and Kreutz, Julian and Sassani, Kiarash and Waechter, Christian and Ausbuettel, Felix and Kano, Fares},
  title = {Cardiogenic shock phenotypes and outcomes under percutaneous left ventricular support: results from a 9-year single-center real-world cohort},
  journal = {Clinical Research in Cardiology},
  year = {2026},
  doi = {10.1007/s00392-026-03055-6}
}
Kostenlos starten →